Pharmacological preclinical comparison of tenecteplase and alteplase for the treatment of acute stroke

Clara Correa‐Paz; María Pérez‐Mato; Mathys Bellemain-Sagnard; Marco González-Domínguez; Pauline Marie; Lara Pérez-Gayol; Esteban López‐Arias; Lucía del Pozo-Filíu; Sonia López-Amoedo; Ana Bugallo-Casal; María Luz Alonso-Alonso; María Candamo-Lourido; María Santamaría-Cadavid; Susana Arias-Rivas; Manuel Rodríguez‐Yáñez; Ramón Iglesias‐Rey; José Castillo; Denis Vivien; Marina Rubio; Francisco Campos

doi:10.1177/0271678x241237427

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Alteplase (rtPA) remains the standard thrombolytic drug for acute ischemic stroke. However, new rtPA-derived molecules, such as tenecteplase (TNK), with prolonged half-lives following a single

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Correa‐Paz et al. (2024) studied this question.

synapsesocial.com/papers/68e75c95b6db6435876d3688 https://doi.org/10.1177/0271678x241237427

View at Publisher

Ask AI

Bookmark

Share

Pharmacological preclinical comparison of tenecteplase and alteplase for the treatment of acute stroke

Ask about this paper

Abstract

Discussion

Cite This Study

Pharmacological preclinical comparison of tenecteplase and alteplase for the treatment of acute stroke

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading